Wegovy HD Results: 21% Average Weight Loss - What the Trials Show

Wegovy HD Results: 21% Average Weight Loss - What the Trials Show

The conversation around weight management has changed dramatically in recent years, largely due to a class of medications known as GLP-1 receptor agonists. Among them, Wegovy (semaglutide) has garnered significant attention for the results seen in its clinical trials. You may have seen headlines about "21% weight loss" with Wegovy HD, the higher 7.2 mg dose that the FDA approved on March 19, 2026.

This article provides a clear, evidence-based look at the clinical trial data for standard Wegovy (2.4 mg) and Wegovy HD (7.2 mg), breaking down what the numbers mean, the timeline for results, and the factors that can influence an individual's journey. It’s about setting realistic expectations based on the science. Consult your healthcare provider before starting any medication.

The Science Behind the Numbers: The STEP Trials

The primary data on Wegovy's effectiveness comes from a series of large-scale, high-quality clinical studies known as the STEP (Semaglutide Treatment Effect in People with Obesity) program. These trials were designed to rigorously evaluate the medication's impact on weight loss in adults with obesity or overweight with at least one weight-related health condition.

The most frequently cited study, STEP 1, was published in The New England Journal of Medicine. It involved nearly 2,000 participants over 68 weeks (about 15 and a half months). All participants received guidance on diet and exercise, but one group received a weekly Wegovy injection while the other received a placebo.

The results were groundbreaking:

• Average Weight Loss: The group taking Wegovy lost an average of 14.9% of their initial body weight.
• Placebo Comparison: The placebo group, who also followed the lifestyle intervention plan, lost an average of 2.4% of their body weight.

This means the average weight loss directly attributable to the medication was over 12 percentage points more than with diet and exercise alone. For a person weighing 230 pounds (104 kg), a 14.9% loss represents a reduction of over 34 pounds (15.5 kg).

Within the STEP 1 trial:

• 86.4% of people taking Wegovy 2.4 mg lost at least 5% of their body weight (a clinically significant milestone).
• 69.1% lost 10% or more, and 50.5% lost 15% or more.
• About one-third (32%) lost 20% or more of their body weight.

So, Where Does the 21% Figure Come From?

The 21% figure comes from a different trial, STEP UP, which tested the higher 7.2 mg dose (Wegovy HD). STEP UP was a 72-week trial in 1,407 adults with obesity (BMI 30 or more) without diabetes, comparing 7.2 mg, 2.4 mg and placebo, all alongside a lifestyle programme. The results:

• Among people who stayed on treatment, average weight loss with 7.2 mg was 20.7% (Novo Nordisk rounds this to about 21%).
• Counting everyone, including people who stopped treatment, average weight loss was 18.7% with 7.2 mg, 15.6% with 2.4 mg and 3.9% with placebo.
• About one in three (31.2%) people on 7.2 mg lost 25% or more of their body weight.

In a companion trial, STEP UP T2D, in adults with obesity and type 2 diabetes, average weight loss with 7.2 mg was 13.2% counting everyone (14.1% among people who stayed on treatment), compared with 10.4% on 2.4 mg and 3.8% on placebo.

So 21% is an average from the higher dose in people without diabetes who kept taking it. It is not a promise: individual results vary widely, and some people lose much less.

A Realistic Timeline for Wegovy Results

Weight loss with Wegovy is a gradual process, not an overnight transformation. The clinical trials lasted 68 weeks for a reason. Understanding the timeline is key to managing expectations.

The First Few Months: Dose Titration

Wegovy treatment begins with a low starting dose that is slowly increased over the first 16 weeks (about four months). This process, known as dose titration, is designed to help the body adjust to the medication and minimize potential side effects, such as nausea.

During this initial period, weight loss may be slower. The goal is to reach the full maintenance dose (2.4 mg) safely. Some people notice a reduction in appetite and changes in food cravings fairly early, but the most significant weight loss typically occurs once the full dose is reached.

Months 5 to 15: The Steady Phase

Once at the maintenance dose, participants in the STEP trials experienced steady and consistent weight loss for many months. Under the US label, the 7.2 mg dose is only an option for adults who have tolerated 2.4 mg for at least 4 weeks and need more weight loss, as judged by their doctor; in STEP UP, the dose was increased in steps over 20 weeks before reaching 7.2 mg. The medication works by mimicking a natural gut hormone that regulates appetite and food intake. This leads to feeling full sooner, staying full longer, and a reduced desire to eat, which helps in maintaining a lower calorie intake over the long term.

It's important to remember that progress isn't always linear. Plateaus are a normal part of any weight loss journey. The key takeaway from the trials is that consistent use over an extended period leads to the most substantial results.

Factors That Can Influence Your Progress

The clinical trials show that Wegovy is a powerful tool, but it works best as part of a comprehensive plan. The participants in the STEP program didn't just take a weekly injection; they also received counseling on diet and physical activity.

Several factors can affect how successful treatment may be:

• Lifestyle Changes: Consistently incorporating healthier eating habits and regular physical activity is crucial. The medication helps manage hunger and cravings, making it easier to stick to these changes.
• Adherence: Taking the medication consistently as prescribed is essential for it to work effectively.
• Starting Point: Individual factors like your starting weight, metabolism, and overall health can play a role.
• Patience and Consistency: The most successful participants were those who stuck with the program for the full 68-week duration of the trial.

More Than Just a Number on the Scale

The benefits observed in the STEP trials went beyond weight loss. Participants who took Wegovy also saw significant improvements in several health markers, including:

• Waist Circumference: A key indicator of visceral fat around the organs.
• Blood Pressure: Both systolic and diastolic readings improved.
• Blood Sugar Levels: Important markers for metabolic health.
• Cholesterol Levels: Improvements in lipid profiles were noted.

These changes highlight that the goal of weight management is not just about aesthetics but about improving overall health and reducing the risk of weight-related conditions.

Side Effects at the Higher Dose

In STEP UP, digestive side effects such as nausea, diarrhoea, vomiting and constipation were more common with 7.2 mg (70.8%) than with 2.4 mg (61.2%) or placebo (42.8%). Altered skin sensation (dysaesthesia), such as tingling, burning or sensitivity, was reported by 22.9% on 7.2 mg versus 6.0% on 2.4 mg.

Get urgent medical help for severe stomach pain that does not go away (it may spread to your back), pain in the upper right abdomen with fever or yellowing of the skin or eyes, signs of a serious allergic reaction, or vomiting or diarrhoea so severe you cannot keep fluids down. If you take insulin or a sulfonylurea, ask your doctor about low blood sugar. Wegovy carries a US boxed warning about thyroid C-cell tumours and must not be used if you or a close relative has had medullary thyroid carcinoma (MTC) or if you have MEN 2.

The results from Wegovy's clinical trials are compelling, offering a clear picture of its potential as a tool for significant and sustained weight loss. With the standard 2.4 mg dose, average weight loss was around 15%; with the 7.2 mg dose in STEP UP, it was 18.7% counting everyone and 20.7% among people who stayed on treatment. Understanding this data can help you have a more informed conversation with your doctor, which is a goal we support at Weight Easy.

This journey is a marathon, not a sprint, and is most effective when combined with lasting lifestyle changes. Consult your healthcare provider before starting any medication.

Sources

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
2. Novo Nordisk. Wegovy US Prescribing Information (revised June 2026). https://www.novo-pi.com/wegovy.pdf
3. European Medicines Agency (EMA). Wegovy (semaglutide) Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
4. Novo Nordisk press release on Wegovy phase 3a data publication. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=45258
5. Mayo Clinic. Semaglutide (Subcutaneous Route) Description and Brand Names. https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730
6. Wharton, S., et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes & Endocrinology, 13(11), 949–963. https://pubmed.ncbi.nlm.nih.gov/40961952/
7. Lingvay, I., et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D). Lancet Diabetes & Endocrinology, 13(11), 935–948. https://pubmed.ncbi.nlm.nih.gov/40961953/
8. Novo Nordisk. Wegovy HD (semaglutide 7.2 mg) approved in the US (19 March 2026). https://www.biospace.com/press-releases/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss
9. U.S. Food and Drug Administration. FDA approves higher-dose semaglutide (19 March 2026). https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide